Technologies for Enhanced Efficacy of DNA Vaccines

Overview

Journal Expert Rev Vaccines

Date 2012 Feb 8

PMID 22309668

Citations 131

Authors

Fadi Saade

Nikolai Petrovsky

Affiliations

Soon will be listed here.

Abstract

Despite many years of research, human DNA vaccines have yet to fulfill their early promise. Over the past 15 years, multiple generations of DNA vaccines have been developed and tested in preclinical models for prophylactic and therapeutic applications in the areas of infectious disease and cancer, but have failed in the clinic. Thus, while DNA vaccines have achieved successful licensure for veterinary applications, their poor immunogenicity in humans when compared with traditional protein-based vaccines has hindered their progress. Many strategies have been attempted to improve DNA vaccine potency including use of more efficient promoters and codon optimization, addition of traditional or genetic adjuvants, electroporation, intradermal delivery and various prime-boost strategies. This review summarizes these advances in DNA vaccine technologies and attempts to answer the question of when DNA vaccines might eventually be licensed for human use.

Citing Articles

Designing and Evaluation of a Plasmid Encoding Immunogenic Epitopes From Eg95-1-6, P29, and GST Against Hydatid Cyst in BALB/c Mice.

Khazaei S, Dalimi A, Pirestani M, Ghafarifar F J Parasitol Res. 2025; 2025:1655679.

PMID: 40041800 PMC: 11876539. DOI: 10.1155/japr/1655679.

DNA vaccines as promising immuno-therapeutics against cancer: a new insight.

Shariati A, Khezrpour A, Shariati F, Afkhami H, Yarahmadi A, Alavimanesh S Front Immunol. 2025; 15:1498431.

PMID: 39872522 PMC: 11769820. DOI: 10.3389/fimmu.2024.1498431.

Augmented immunogenicity of the HPV16 DNA vaccine via dual adjuvant approach: integration of CpG ODN into plasmid backbone and co-administration with IL-28B gene adjuvant.

Zhou Y, Zhang T, Wang Z, Xu X Virol J. 2025; 22(1):3.

PMID: 39780219 PMC: 11707914. DOI: 10.1186/s12985-024-02604-7.

Discovery of Therapeutic Antibodies Targeting Complex Multi-Spanning Membrane Proteins.

Stephens A, Wilkinson T BioDrugs. 2024; 38(6):769-794.

PMID: 39453540 PMC: 11530565. DOI: 10.1007/s40259-024-00682-1.

A comprehensive comparison of DNA and RNA vaccines.

Wang C, Yuan F Adv Drug Deliv Rev. 2024; 210:115340.

PMID: 38810703 PMC: 11181159. DOI: 10.1016/j.addr.2024.115340.

References

Mor G, Yamshchikov G, Sedegah M, Takeno M, Wang R, Houghten R . Induction of neonatal tolerance by plasmid DNA vaccination of mice. J Clin Invest. 1996; 98(12):2700-5. PMC: 507733. DOI: 10.1172/JCI119094. View

Perales M, Yuan J, Powel S, Gallardo H, Rasalan T, Gonzalez C . Phase I/II study of GM-CSF DNA as an adjuvant for a multipeptide cancer vaccine in patients with advanced melanoma. Mol Ther. 2008; 16(12):2022-9. PMC: 3909666. DOI: 10.1038/mt.2008.196. View

Fagone P, Shedlock D, Bao H, Kawalekar O, Yan J, Gupta D . Molecular adjuvant HMGB1 enhances anti-influenza immunity during DNA vaccination. Gene Ther. 2011; 18(11):1070-7. PMC: 4141626. DOI: 10.1038/gt.2011.59. View

Barouch D, Craiu A, Kuroda M, Schmitz J, Zheng X, Santra S . Augmentation of immune responses to HIV-1 and simian immunodeficiency virus DNA vaccines by IL-2/Ig plasmid administration in rhesus monkeys. Proc Natl Acad Sci U S A. 2000; 97(8):4192-7. PMC: 18194. DOI: 10.1073/pnas.050417697. View

Kim J, Trivedi N, Nottingham L, Morrison L, Tsai A, Hu Y . Modulation of amplitude and direction of in vivo immune responses by co-administration of cytokine gene expression cassettes with DNA immunogens. Eur J Immunol. 1998; 28(3):1089-103. DOI: 10.1002/(SICI)1521-4141(199803)28:03<1089::AID-IMMU1089>3.0.CO;2-L. View

Jia R, Guo J, Fan M, Bian Z, Chen Z, Fan B . Immunogenicity of CTLA4 fusion anti-caries DNA vaccine in rabbits and monkeys. Vaccine. 2006; 24(24):5192-200. DOI: 10.1016/j.vaccine.2006.03.090. View

Petrovsky N . Freeing vaccine adjuvants from dangerous immunological dogma. Expert Rev Vaccines. 2008; 7(1):7-10. DOI: 10.1586/14760584.7.1.7. View

Chong S, Egan M, Kutzler M, Megati S, Masood A, Roopchard V . Comparative ability of plasmid IL-12 and IL-15 to enhance cellular and humoral immune responses elicited by a SIVgag plasmid DNA vaccine and alter disease progression following SHIV(89.6P) challenge in rhesus macaques. Vaccine. 2007; 25(26):4967-82. DOI: 10.1016/j.vaccine.2006.11.070. View

Hu X, Chen S, Li J, Yu D, Yi-Zhang , Cai H . An IL-15 adjuvant enhances the efficacy of a combined DNA vaccine against Brucella by increasing the CD8+ cytotoxic T cell response. Vaccine. 2010; 28(12):2408-15. DOI: 10.1016/j.vaccine.2009.12.076. View

10.

Mbow M, De Gregorio E, Ulmer J . Alum's adjuvant action: grease is the word. Nat Med. 2011; 17(4):415-6. DOI: 10.1038/nm0411-415. View

11.

Brave A, Gudmundsdotter L, Sandstrom E, Haller B, Hallengard D, Maltais A . Biodistribution, persistence and lack of integration of a multigene HIV vaccine delivered by needle-free intradermal injection and electroporation. Vaccine. 2010; 28(51):8203-9. PMC: 7126493. DOI: 10.1016/j.vaccine.2010.08.108. View

12.

Westermann J, Nguyen-Hoai T, Baldenhofer G, Hopken U, Lipp M, Dorken B . CCL19 (ELC) as an adjuvant for DNA vaccination: induction of a TH1-type T-cell response and enhancement of antitumor immunity. Cancer Gene Ther. 2007; 14(6):523-32. DOI: 10.1038/sj.cgt.7701042. View

13.

Klencke B, Matijevic M, Urban R, Lathey J, Hedley M, Berry M . Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: a Phase I study of ZYC101. Clin Cancer Res. 2002; 8(5):1028-37. View

14.

Kim J, Yang J, Manson K, Weiner D . Modulation of antigen-specific cellular immune responses to DNA vaccination in rhesus macaques through the use of IL-2, IFN-gamma, or IL-4 gene adjuvants. Vaccine. 2001; 19(17-19):2496-505. DOI: 10.1016/s0264-410x(00)00479-5. View

15.

Sin J . Suppression of antitumour protective cytotoxic T lymphocyte responses to a human papillomavirus 16 E7 DNA vaccine by coinjection of interleukin-12 complementary DNA: involvement of nitric oxide in immune suppression. Immunology. 2009; 128(1 Suppl):e707-17. PMC: 2753902. DOI: 10.1111/j.1365-2567.2009.03068.x. View

16.

Kutzler M, Weiner D . DNA vaccines: ready for prime time?. Nat Rev Genet. 2008; 9(10):776-88. PMC: 4317294. DOI: 10.1038/nrg2432. View

17.

Sardesai N, Weiner D . Electroporation delivery of DNA vaccines: prospects for success. Curr Opin Immunol. 2011; 23(3):421-9. PMC: 3109217. DOI: 10.1016/j.coi.2011.03.008. View

18.

de Andres X, Reina R, Ciriza J, Crespo H, Glaria I, Ramirez H . Use of B7 costimulatory molecules as adjuvants in a prime-boost vaccination against Visna/Maedi ovine lentivirus. Vaccine. 2009; 27(34):4591-600. DOI: 10.1016/j.vaccine.2009.05.080. View

19.

Kwissa M, Kroger A, Hauser H, Reimann J, Schirmbeck R . Cytokine-facilitated priming of CD8+ T cell responses by DNA vaccination. J Mol Med (Berl). 2003; 81(2):91-101. DOI: 10.1007/s00109-002-0395-6. View

20.

Barbon C, Baker L, Lajoie C, Ramstedt U, Hedley M, Luby T . In vivo electroporation enhances the potency of poly-lactide co-glycolide (PLG) plasmid DNA immunization. Vaccine. 2010; 28(50):7852-64. DOI: 10.1016/j.vaccine.2010.09.078. View